UCB SA (Euronext Brussels: UCB) has dedicated the future site of its approximately $2 billion biologics manufacturing campus at Rowen in Gwinnett County, Georgia, marking another development milestone for its first U.S. biologics manufacturing campus. The October 9, 2026 ceremony advances a project intended to support commercial production of recently approved and future biologic medicines, although construction, manufacturing qualification and regulatory requirements must be addressed before commercial production can begin.
The planned campus will cover approximately 460,000 square feet on a 79-acre site, forming part of a broader strategy to expand UCB’s manufacturing capabilities closer to one of its most important pharmaceutical markets. The company expects the investment to generate approximately $5 billion in economic impact, create around 330 permanent highly skilled positions and support more than 1,000 construction jobs. Those figures reflect projected benefits rather than completed expenditure, realised economic activity or existing employment.
The site dedication follows UCB’s June 2025 announcement of plans to expand U.S. biologics manufacturing and its March 2026 selection of Georgia as the preferred location. The latest ceremony therefore represents progress in an established capital investment programme rather than a newly announced $2 billion commitment. Its commercial significance lies in whether the facility can eventually provide flexible, reliable and regulatory-compliant capacity for a growing portfolio of complex therapies.
Why is UCB investing $2 billion in Georgia as demand for biologic medicines accelerates?
UCB’s manufacturing expansion is closely connected to a period of substantial commercial growth, particularly in immunology, where demand for its newer medicines has increased significantly. Biological medicines require complex manufacturing processes, specialised production infrastructure and extensive quality controls, making their supply requirements different from those of conventional small-molecule pharmaceuticals. Expanding production capacity is consequently a long-term strategic decision that must account for expected demand, product development timelines and the cost of maintaining reliable manufacturing operations.
The company’s July 2026 half-year results demonstrate why additional manufacturing flexibility has become increasingly relevant. UCB reported first-half revenue of €4.27 billion, representing growth of 22%, while net sales increased 23% to approximately €4.09 billion. Adjusted earnings before interest, taxes, depreciation and amortisation reached €1.74 billion, reflecting an adjusted EBITDA margin of 40.7%.
A major contributor was BIMZELX (bimekizumab), UCB’s interleukin-17A and interleukin-17F inhibitor used across several inflammatory conditions under its respective approved indications. BIMZELX generated €1.528 billion in global net sales during the first six months of 2026, compared with €799 million in the corresponding period of 2025, representing reported growth of approximately 91%. UCB also increased its BIMZELX peak annual sales ambition to at least €7 billion, reflecting management’s expectations rather than guaranteed future revenue.
This rapid commercial expansion creates a stronger rationale for investing in manufacturing infrastructure before additional capacity becomes essential. Production networks need sufficient flexibility to accommodate changing demand across approved indications, geographic markets and potential future product launches. However, UCB has not publicly assigned a definitive product-by-product manufacturing portfolio to the Georgia campus, meaning the facility should not yet be described as a confirmed production site for any particular medicine.
How will the Georgia biologics campus change UCB’s existing global manufacturing network?
The Georgia project is intended to complement UCB’s established international manufacturing and supply network rather than replace it. The company already operates production capabilities in Europe, including its Bulle facility in Switzerland, which combines expertise in biological and chemical manufacturing. UCB has also invested in manufacturing infrastructure in Belgium, while maintaining relationships with external manufacturing partners to support commercial supply.
In its March 2026 announcement, UCB indicated that the future Georgia facility is expected to operate continuously once operational and primarily serve the U.S. market. This planned production model would create a substantial domestic manufacturing presence, potentially giving the company greater flexibility in coordinating manufacturing, product release and supply planning. Actual manufacturing volumes, however, will depend on the products assigned to the site, installed equipment, process performance and successful qualification.
The project also sits alongside UCB’s strategy of expanding relationships with U.S.-based contract manufacturing organisations. In June 2025, the company identified external manufacturing partnerships as an important component of its capacity expansion plans, suggesting that the new campus is part of a broader supply network strategy rather than a complete move toward internal production. Contract manufacturers may continue to provide flexibility, specialised technologies or additional capacity even after the Georgia facility becomes operational.
This combination of internal manufacturing and external partnerships offers potential operational advantages, but those advantages are not automatic. Managing production across different facilities requires consistent quality systems, carefully controlled technology transfer and effective inventory coordination. Any future redistribution of products between manufacturing sites must also preserve the regulatory and technical requirements applicable to each medicine.
What must happen before UCB’s Georgia facility can begin commercial biologics production?
Although the October ceremony demonstrates progress in site development, it does not establish that manufacturing infrastructure has been completed or qualified. UCB has not disclosed a definitive commercial production start date, installed manufacturing capacity or a detailed schedule for individual product transfers in the latest announcement. Consequently, the project remains a future supply investment rather than evidence of immediately available U.S. biologics manufacturing capacity.
Biologics production requires tightly controlled processes because manufacturing conditions can influence product quality and consistency. Facilities must establish appropriate systems for raw materials, environmental monitoring, equipment operation, process control, contamination prevention, quality testing and batch documentation. Production equipment and manufacturing processes must undergo qualification and validation appropriate to their intended uses before commercial manufacturing can proceed.
Regulatory oversight adds another important dimension. Where production of an already licensed biological medicine is introduced at a new facility, the manufacturer must assess the applicable chemistry, manufacturing and controls requirements and determine whether regulatory submissions or approvals are necessary before distributing products manufactured there. Requirements under the United States Food and Drug Administration’s biologics regulations depend on the nature of the manufacturing change and its potential effect on product quality.
For UCB, this means that completing the buildings and installing equipment will represent only part of the operational transition. The company will also need trained personnel, functioning quality systems, validated manufacturing processes and the necessary regulatory arrangements for the products it intends to manufacture. The interval between construction completion and routine commercial supply could therefore be materially influenced by technical readiness and product-specific requirements.
Can artificial intelligence and automation improve manufacturing efficiency at UCB’s new U.S. campus?
UCB intends to develop the Georgia campus around a digital-first manufacturing approach incorporating artificial intelligence, robotics and advanced automation. These technologies are increasingly relevant to biologics manufacturing because production involves complex processes that benefit from careful monitoring, consistent execution and extensive data collection. Their potential value lies in supporting manufacturing quality, operating efficiency and effective production planning rather than simply reducing the need for manual intervention.
Automated systems can help standardise selected manufacturing operations, while digital production records and integrated monitoring tools can improve the availability of process information. Advanced analytical systems may also assist manufacturers in identifying process deviations, understanding manufacturing variability and making better-informed operational decisions. The commercial value of these capabilities ultimately depends on whether they improve measurable outcomes such as process consistency, yield, equipment utilisation or production reliability.
However, artificial intelligence applications in regulated pharmaceutical manufacturing must operate within appropriate quality and validation frameworks. Automated decisions that influence critical manufacturing parameters require suitable controls, documented oversight and assurance that systems perform consistently for their intended purposes. Digital infrastructure must also address data integrity, cybersecurity and the reliability of connections between manufacturing and quality systems.
UCB’s technology strategy is therefore an opportunity to incorporate modern manufacturing architecture into a new facility rather than retrofit an older production environment. Nevertheless, the company has not reported operating performance data demonstrating that the planned technologies will deliver specific productivity improvements at the Georgia site. Such benefits will become assessable only as systems are installed, qualified and used in validated manufacturing processes.
Why could BIMZELX and UCB’s emerging pipeline influence future capacity requirements?
BIMZELX provides an important commercial reference point for understanding UCB’s expanding manufacturing needs, but the company’s pipeline introduces additional complexity. Different biologic medicines can have distinct production processes, quality requirements, formulation characteristics and capacity needs. A manufacturing facility designed for future flexibility must therefore balance the immediate requirements of marketed products with potential longer-term demand from therapies that remain under development.
UCB’s broader immunology and neurology portfolio includes medicines such as RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan), although their manufacturing processes and technology requirements differ. The company is also developing additional investigational therapies, including galvokimig and cizutamig, through clinical programmes. These assets demonstrate the breadth of its pipeline but do not establish that they will be manufactured in Georgia or ultimately receive regulatory approval.
This distinction is especially relevant when evaluating a large manufacturing investment against future product opportunities. A potential medicine may require different equipment, production processes or manufacturing technologies from those used for established commercial products. Even where a facility has physical expansion capacity, introducing another therapy can involve substantial technical development and regulatory work.
The Georgia investment could provide UCB with greater long-term manufacturing options if its commercial portfolio continues expanding. Its ultimate usefulness will depend partly on how closely the facility’s capabilities match the manufacturing needs of medicines that achieve regulatory approval and commercial demand. Capacity planning will also have to accommodate uncertainty in future clinical development, market adoption and the timing of product launches.
What does UCB’s $2 billion Georgia investment mean for jobs and the regional life sciences industry?
The economic significance of the project extends beyond pharmaceutical production because the planned campus is expected to become a major industrial presence within the Rowen innovation district. The project occupies 79 acres within a much larger planned research, education and business development community in Gwinnett County. Its selection provides Rowen with a substantial biopharmaceutical anchor tenant and a potential foundation for attracting related scientific, technical and manufacturing activity.
UCB expects approximately 330 permanent highly skilled jobs and more than 1,000 construction positions to be associated with the investment. The permanent workforce is likely to require expertise across manufacturing operations, engineering, process sciences, quality assurance, quality control and other specialised functions, although the precise staffing mix has not been fully detailed. Employment creation will depend on development progress, operational requirements and the facility’s eventual production configuration.
The company already maintains its U.S. headquarters in metropolitan Atlanta, where it established a corporate presence in 1993. According to the October announcement, UCB employs more than 400 people in Georgia and more than 2,000 across the United States. The new campus would consequently deepen an existing regional commitment rather than introduce UCB to the state for the first time.
UCB has also indicated that it is seeking partnerships with universities, schools and workforce development organisations to support future biomanufacturing talent requirements. Developing that talent base could be commercially important because sophisticated biologics facilities depend on employees who understand regulated manufacturing processes, digital systems and pharmaceutical quality expectations. Recruitment and training will become increasingly relevant as the project progresses toward operational readiness.
The company’s approximately $5 billion economic impact estimate should be distinguished from the direct investment commitment of approximately $2 billion. Economic impact projections typically encompass a wider range of direct, indirect and induced economic activity, while the precise outcome depends on spending, employment, supplier activity and the modelling assumptions used. The projection should not be interpreted as guaranteed local revenue, company earnings or annual economic output.
How does UCB’s Georgia manufacturing strategy fit the changing U.S. pharmaceutical policy environment?
UCB’s manufacturing expansion is also taking place against a changing U.S. pharmaceutical policy backdrop, where domestic production, medicine affordability and supply resilience have become closely connected commercial considerations. Establishing manufacturing capacity within the United States can create additional sourcing and logistical options, although the economic consequences vary depending on the products involved and the structure of the global supply chain. Local manufacturing does not automatically eliminate dependence on imported raw materials, specialised components or international production partners.
On August 31, 2026, UCB announced an agreement with the U.S. government covering medicine pricing and continued investment in American pharmaceutical operations. The company indicated that the arrangement involved a more balanced pricing approach for future medicine launches across developed markets, participation in the government’s GENEROUS programme and continued domestic manufacturing investment. UCB also stated that, as a result of the agreement, it would not be subject to Section 232 pharmaceutical tariffs on current products or future pricing mandates, while the agreement’s specific terms remained confidential.
That agreement adds policy context to the Georgia expansion, but it should not be interpreted as evidence that the manufacturing campus was established solely to obtain tariff protection. UCB’s initial U.S. capacity expansion plans preceded the August agreement, and its March 2026 site-selection announcement placed substantial emphasis on long-term commercial demand and supply resilience. The more durable strategic argument is that manufacturing capacity closer to a major market can provide operational flexibility across different policy environments.
The financial benefits of domestic production will still depend on construction costs, ongoing manufacturing economics, product allocation and capacity utilisation. New facilities can require substantial investment before contributing meaningfully to commercial supply, while the cost structure of advanced biologics production differs from traditional pharmaceutical manufacturing. UCB will therefore need to balance supply reliability and strategic flexibility against the capital and operating costs associated with its expanded footprint.
What does UCB’s stock performance reveal about expectations for its manufacturing expansion?
UCB shares closed at €203.50 on Euronext Brussels on October 9, 2026, representing a gain of approximately 0.84% from the previous session. The stock remained substantially below its reported 52-week high of €289.50 and near the lower end of its recent trading range. However, the Georgia site-dedication announcement was distributed after the Brussels market had closed, meaning the October 9 price movement should not be interpreted as a reaction to that particular disclosure.
The company’s latest reported financial performance provides a more substantive basis for assessing its ability to pursue a large capital investment programme. Strong first-half growth in BIMZELX sales, improving adjusted profitability and upgraded 2026 guidance indicate that UCB entered the second half of the year with substantial commercial momentum. At the same time, a multiyear manufacturing project will create investment requirements before the associated infrastructure can deliver operating benefits.
The Georgia campus is best understood as a longer-term manufacturing and capital-allocation commitment rather than an immediate revenue catalyst. Its potential financial contribution will depend on capital spending, production volumes, manufacturing costs and the allocation of approved commercial products to the facility. Those variables have not yet been disclosed in sufficient detail to estimate a reliable investment return.
For UCB’s manufacturing strategy, the next meaningful developments will be evidence of physical construction progress, greater clarity on the facility’s production configuration and disclosure of an operational readiness schedule. Subsequent milestones involving process validation, regulatory requirements and manufacturing scale-up will help establish when the campus could begin contributing to commercial supply. Until those developments occur, the approximately $2 billion commitment represents a substantial expansion of planned capacity rather than an increase in medicines already available to patients.
UCB’s October site dedication has therefore moved an ambitious U.S. manufacturing project another stage forward without resolving its principal operational uncertainties. Strong demand for BIMZELX and continued pipeline investment provide a commercial rationale for additional biologics capacity, while Georgia offers an established corporate base and a developing life sciences ecosystem. The project’s ultimate contribution will be determined by whether UCB can convert its planned 460,000-square-foot facility into qualified, reliable production capacity that matches the needs of its future commercial portfolio.
